• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion Summary.

作者信息

Virgo Katherine S, Rumble R Bryan, Singer Eric A

机构信息

Emory University, Atlanta, GA; American Society of Clinical Oncology, Alexandria, VA; and Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.

出版信息

J Oncol Pract. 2017 Jul;13(7):459-461. doi: 10.1200/JOP.2017.022970. Epub 2017 Apr 26.

DOI:10.1200/JOP.2017.022970
PMID:28445101
Abstract
摘要

相似文献

1
Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion Summary.初治化疗的去势抵抗性前列腺癌男性患者的二线激素治疗：美国临床肿瘤学会临时临床意见摘要
J Oncol Pract. 2017 Jul;13(7):459-461. doi: 10.1200/JOP.2017.022970. Epub 2017 Apr 26.
2
Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion.化疗初治去势抵抗性前列腺癌的二线激素治疗：美国临床肿瘤学会临时临床意见。
J Clin Oncol. 2017 Jun 10;35(17):1952-1964. doi: 10.1200/JCO.2017.72.8030. Epub 2017 Apr 25.
3
Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.醋酸阿比特龙治疗初治转移性去势抵抗性前列腺癌患者时骨靶向治疗的影响：研究COU-AA-302的事后分析
Eur Urol. 2015 Oct;68(4):570-7. doi: 10.1016/j.eururo.2015.04.032. Epub 2015 May 16.
4
Austrian recommendations on Targeted Hormone Therapy for metastatic, castration-resistant prostate cancer.奥地利关于转移性去势抵抗性前列腺癌靶向激素治疗的建议。
Wien Klin Wochenschr. 2016 Feb;128(3-4):156-63. doi: 10.1007/s00508-015-0945-x. Epub 2016 Feb 1.
5
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.醋酸阿比特龙联合泼尼松对比安慰剂联合泼尼松治疗化疗初治转移性去势抵抗性前列腺癌患者（COU-AA-302）：一项随机、双盲、安慰剂对照的 3 期研究的最终总生存分析。
Lancet Oncol. 2015 Feb;16(2):152-60. doi: 10.1016/S1470-2045(14)71205-7. Epub 2015 Jan 16.
6
Prostate cancer: Developing novel approaches to castration-sensitive disease.前列腺癌：开发针对去势敏感性疾病的新方法。
Cancer. 2017 Jan 1;123(1):29-42. doi: 10.1002/cncr.30329. Epub 2016 Nov 1.
7
Targeting the mechanisms of progression in castration-resistant prostate cancer.
Eur Urol. 2015 Mar;67(3):480-1. doi: 10.1016/j.eururo.2014.11.024. Epub 2014 Nov 21.
8
Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.既往内分泌治疗对醋酸阿比特龙治疗转移性去势抵抗性前列腺癌临床疗效的影响：3期随机研究的事后分析
Eur Urol. 2016 May;69(5):924-32. doi: 10.1016/j.eururo.2015.10.021. Epub 2015 Oct 24.
9
Galeterone activity in castration-resistant prostate cancer.加列酮在去势抵抗性前列腺癌中的活性
Lancet Oncol. 2015 Jan;16(1):e10. doi: 10.1016/S1470-2045(14)71165-9. Epub 2014 Nov 28.
10
First-line use of novel hormonal agents in prostate cancer: a critical appraisal.新型激素药物在前列腺癌中的一线应用：批判性评估
Clin Adv Hematol Oncol. 2018 Apr;16(4):289-295.

引用本文的文献

1
Treatment patterns for patients with BRCA1/2-positive metastatic castration-resistant prostate cancer.BRCA1/2 阳性转移性去势抵抗性前列腺癌患者的治疗模式
Oncologist. 2025 Jan 17;30(1). doi: 10.1093/oncolo/oyae183.
2
Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second-line antiandrogen therapy era.二线抗雄激素治疗时代诊断为转移性前列腺癌患者的生存状况略有改善。
Cancer Med. 2021 Nov;10(22):7909-7920. doi: 10.1002/cam4.4074. Epub 2021 Oct 29.
3
Efficacy and safety of abiraterone acetate plus prednisolone in patients with early metastatic castration-resistant prostate cancer who failed first-line androgen-deprivation therapy: a single-arm, phase 4 study.
醋酸阿比特龙联合泼尼松治疗一线去势治疗失败的转移性去势抵抗性前列腺癌患者的疗效和安全性：一项单臂、4 期研究。
Jpn J Clin Oncol. 2021 Apr 1;51(4):544-551. doi: 10.1093/jjco/hyaa225.
4
Effects of miR-129-3p on biological functions of prostate cancer cells through targeted regulation of Smad3.miR-129-3p通过靶向调控Smad3对前列腺癌细胞生物学功能的影响
Oncol Lett. 2020 Feb;19(2):1195-1202. doi: 10.3892/ol.2019.11216. Epub 2019 Dec 13.
5
Management algorithms for prostate-specific antigen progression in prostate cancer: Biochemical recurrence after definitive therapy and progression to non-metastatic castrate-resistant prostate cancer.前列腺癌中前列腺特异性抗原进展的管理算法：确定性治疗后的生化复发及进展为非转移性去势抵抗性前列腺癌。
Can Urol Assoc J. 2019 Dec;13(12):420-426. doi: 10.5489/cuaj.5600. Epub 2019 Feb 7.